Lower SBP Target for Blacks May Benefit Cognitive Function

Share this content:
Lower SBP Target for Blacks May Benefit Cognitive Function
Lower SBP Target for Blacks May Benefit Cognitive Function

TUESDAY, Aug. 22, 2017 (HealthDay News) -- For seniors and particularly blacks with hypertension, lowering systolic blood pressure to 120 mm Hg or lower may help prevent cognitive decline, according to a report published online Aug. 21 in JAMA Neurology.

From 1997 to 2007, Ihab Hajjar, M.D., an associate professor of medicine at the Emory University School of Medicine in Atlanta, and colleagues collected data on 1,657 adults aged 70 to 79 who were being treated for hypertension and showed no signs of cognitive decline. During the study period, cognition was assessed using the Modified Mini-Mental State Examination four times and the Digit Symbol Substitution Test five times.

The researchers found that scores on the cognitive tests were linked with the patient's systolic blood pressure. The higher the systolic number, the more test scores declined. Moreover, the declines in test scores were greater in blacks with high systolic blood pressures than they were among whites with similar blood pressure readings.

"The negative health effects of higher blood pressure are more prevalent in blacks, especially related to kidney disease, stroke, and cardiovascular health," Hajjar told HealthDay. "Therefore, it is conceivable that lowering blood pressure in this population would have a far greater impact than other groups for the cognitive effects as well."

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »